Fintech PR
A Voice for Modern Medicine: Augnito and Cloud Solutions Partner to Deliver AI-powered Healthcare in The Kingdom
RIYADH, Saudi Arabia, April 4, 2024 /PRNewswire/ — Renowned Medical Voice AI innovators, Augnito, made a momentous announcement during the prestigious LEAP 2024 technology conference. The company has established a pioneering partnership with Cloud Solutions, an industry-leader in digital transformation in the Middle East. This groundbreaking collaboration holds immense potential to revolutionize the healthcare landscape by significantly improving the efficiency, accuracy, and accessibility of healthcare services for patients and providers alike.
“At Cloud Solutions,we have always prioritized both innovation and collaboration. We actively seek out global solutions that not only leverage the latest technology but are also integrative and supportive of evolving organizational goals. Augnito is a company that fits our criteria perfectly. They have showcased an unrivalled commitment to customer success and collaboration, as well as a rapid pace of innovation in the past three years. We look forward to working with them,” said Abdulelah AlMayman,CEO of Cloud Solutions. Elaborating on the long-term vision for this collaboration, he added “Both entities envision an impact far beyond individual healthcare providers – we see a future in which there is a fully interoperable regional electronic health record (EHR) system in The Kingdom of Saudi Arabia.This partnership is a crucial stepping-stone towards this goal.”
The digital transformation partner was highly impressed by Augnito’s cutting-edge Ambient Clinical Intelligence technology, recognizing the remarkable benefits of integrating it with their flagship VIDA Hospital Information System (HIS). Ambient Clinical Intelligence employs Far Field Speech Recognition, Multi-lingual Speech Recognition (including Arabic) and Speaker Diarization, as well as Generative AI technology to enhance and optimize the capturing and structuring of Electronic Health Record (EHR) data.
Augnito’s track record showcases how Clinical Voice AI softwares are already automating and streamlining administrative tasks to enable faster turnaround times (saving over 3 hours per day for doctors). Their products also ensure accuracy, smoother workflows, improved productivity, and resource optimization. In fact, Augnito’s recent integration with one of the largest hospital chains in Asia highlighted a staggering 21x return on investment – achieved in just 6 months.
Speaking on the state of the industry and partnering with Cloud Solutions, Rustom Lawyer, Co-Founder & CEO of Augnito said, “In today’s demanding healthcare landscape, clinicians need solutions that simultaneously free up their time and augment their capabilities. They need to be empowered – and that is precisely what we aim to do via this partnership. We are delighted to now be working directly with the largest healthcare provider in the Gulf Corporation Council (GCC), and we thank the team at Cloud Solutions for their faith and support in our technology. We look forward to comprehensively enhancing healthcare in the Kingdom of Saudi Arabia with the most intuitive AI solutions in the world.”
Augnito is a supporter of The Kingdom’s Vision 2030 roadmap and hopes to create significant and ongoing impact in the Middle East. They have also partnered with Prime Hospitals,RAK Hospitals, King’s College Hospital London (Dubai), and ATTIEH Medico in the region.
About Cloud Solutions Cloud Solutions is a leading force in digital healthcare transformation, boasting over two decades of experience in the Middle East. Their mission: to empower healthcare providers with cutting-edge technology solutions. Cloud Solutions seamlessly integrates medical equipment, clinical networking, and healthcare informatics into comprehensive, enterprise-level solutions. This integrated approach positions them at the forefront of the value chain, delivering services and solutions that directly benefit healthcare organizations. The company leverages its deep industry knowledge and state-of-the-art AI-powered solutions to shape the future of healthcare delivery and is a trusted partner to both government and private entities.
For more information,please visit https://cloudsolutions.com.sa/en/
About Augnito
Augnito is an intuitive and advanced Voice-AI solution innovator, revolutionizing clinical documentation in the global healthcare market. Their proprietary AI-based clinical speech recognition, natural language understanding (NLU) & generative AI technologies enable ergonomic data entry with 99% accuracy, anywhere, from any device. Augnito helps streamline clinical workflows, makes healthcare intelligence securely accessible, and ensures that physicians have more time to concentrate on their primary concern: patient care. Their solutions are currently in use at more than 375 hospitals, across more than 25 countries.
Photo – https://mma.prnewswire.com/media/2378593/Augnito.jpg
For more information or assistance, please visit augnito.ai or email [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/a-voice-for-modern-medicine-augnito-and-cloud-solutions-partner-to-deliver-ai-powered-healthcare-in-the-kingdom-302108238.html
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News6 days ago
Clayfin Technologies and Jana Small Finance Bank Honored with Prestigious IBSi Digital Banking Award 2024
-
Latest News5 days ago
Trakx launches a new product: Trakx USDc Earn CTI powered by OpenTrade
-
Latest News7 days ago
Nium Expands Regional Footprint in Asia; Signs Partnership MOU with Indonesian Payments Infrastructure Leader, Artajasa
-
Latest News6 days ago
HANDSHAKE SPEAKEASY IN MEXICO CITY NAMED AS THE BEST BAR IN NORTH AMERICA AS RANKING OF NORTH AMERICA’S 50 BEST BARS IS REVEALED AT THIRD ANNUAL AWARDS CEREMONY
-
Latest News6 days ago
SDAX Unveils World’s First Securitised Gold Tokens for Digital Exchange Users
-
Latest News6 days ago
BINGHATTI LAUNCHES ITS DEBUT PROJECT ADJACENT TO DUBAI HILLS
-
Latest News6 days ago
Allfunds has partnered with Google Cloud to leverage AI-powered innovation and optimize its infrastructure.
-
Latest News5 days ago
Venom Blockchain and United Network Forge Strategic Partnership to Power Next-Generation Payment Systems